Literature DB >> 21195754

The iron-chelating drug triapine causes pronounced mitochondrial thiol redox stress.

Judith M Myers1, William E Antholine, Jacek Zielonka, Charles R Myers.   

Abstract

Triapine (Tp) is an iron chelator with activity against several types of cancer. Iron-Tp [Fe(III)(Tp)(2)] can be redox-cycled to generate reactive oxygen species that may contribute to its cytotoxicity. However, evidence for this mechanism in cells is limited. The cytosolic and mitochondrial thioredoxins (Trx1 and Trx2, respectively) are essential for cell survival. They are normally maintained in the reduced state, and support the function of many intracellular proteins including the peroxiredoxins (Prxs). Their redox status can indicate oxidant stress in their respective subcellular compartments. Tp treatment of human lung A549 cells caused almost complete oxidation of Trx2 and its dependent peroxiredoxin (Prx3), but there was no effect on Trx1 redox status. Significant inhibition of total TrxR activity did not occur until Tp levels were 4-fold above those needed to cause Trx2 oxidation. While Tp caused a 36-45% decline in reduced glutathione (GSH) levels, GSH accounted for >99% of the total glutathione in the absence and presence of Tp. In vitro studies demonstrated that cysteine reduces Fe(III)(Tp)(2) to Fe(II)(Tp)(2), and cysteine was faster and more efficient than reduced glutathione (GSH) in this regard. Fe(III)(Tp)(2) also mediated the oxidation of purified Trx2 in vitro. Thus, Fe(III)(Tp)(2) itself, and/or various reactive species that may result from its redox cycling, could account for Trx2 and Prx3 oxidation in Tp-treated cells. The striking difference between the effects on Trx2 and Trx1 implies a pronounced thiol redox stress that is largely directed at the mitochondria. These previously unrecognized effects of Tp could contribute to its overall cytotoxicity.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21195754     DOI: 10.1016/j.toxlet.2010.12.017

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  7 in total

1.  Prooxidant and antioxidant properties of salicylaldehyde isonicotinoyl hydrazone iron chelators in HepG2 cells.

Authors:  Andres A Caro; Ava Commissariat; Caroline Dunn; Hyunjoo Kim; Salvador Lorente García; Allen Smith; Harrison Strang; Jake Stuppy; Linda P Desrochers; Thomas E Goodwin
Journal:  Biochim Biophys Acta       Date:  2015-08-11

Review 2.  The effects of acrolein on the thioredoxin system: implications for redox-sensitive signaling.

Authors:  Charles R Myers; Judith M Myers; Timothy D Kufahl; Rachel Forbes; Adam Szadkowski
Journal:  Mol Nutr Food Res       Date:  2011-08-03       Impact factor: 5.914

Review 3.  Iron-targeting antitumor activity of gallium compounds and novel insights into triapine(®)-metal complexes.

Authors:  Christopher R Chitambar; William E Antholine
Journal:  Antioxid Redox Signal       Date:  2012-10-03       Impact factor: 8.401

4.  Redox activation of Fe(III)-thiosemicarbazones and Fe(III)-bleomycin by thioredoxin reductase: specificity of enzymatic redox centers and analysis of reactive species formation by ESR spin trapping.

Authors:  Judith M Myers; Qing Cheng; William E Antholine; Balaraman Kalyanaraman; Aleksandra Filipovska; Elias S J Arnér; Charles R Myers
Journal:  Free Radic Biol Med       Date:  2013-02-26       Impact factor: 7.376

Review 5.  Cancer cells with irons in the fire.

Authors:  Laura M Bystrom; Stefano Rivella
Journal:  Free Radic Biol Med       Date:  2014-05-14       Impact factor: 7.376

6.  Ribonucleotide reductase inhibition by metal complexes of Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone): a combined experimental and theoretical study.

Authors:  Ana Popović-Bijelić; Christian R Kowol; Maria E S Lind; Jinghui Luo; Fahmi Himo; Eva A Enyedy; Vladimir B Arion; Astrid Gräslund
Journal:  J Inorg Biochem       Date:  2011-07-31       Impact factor: 4.155

7.  3-Chloro-N'-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy.

Authors:  Federica Sarno; Chiara Papulino; Gianluigi Franci; Jeanette H Andersen; Bastien Cautain; Colombina Melardo; Lucia Altucci; Angela Nebbioso
Journal:  Front Pharmacol       Date:  2018-09-07       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.